Drug name - Tibsovo

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9850277 SERVIER Therapeutically active compositions and their methods of use
Jan, 2033

(10 years from now)

US9474779 SERVIER Therapeutically active compositions and their methods of use
Aug, 2033

(10 years from now)

CN104136411B SERVIER Therapy Active Compound And Using Method Thereof
Jan, 2032

(9 years from now)

CN106496090A SERVIER Therapy Active Compound And Using Method Thereof
Jan, 2032

(9 years from now)

CN106496090B SERVIER Therapeutically Active Compounds And Methods Of Use Thereof
Jan, 2032

(9 years from now)

CN104136411A SERVIER Therapeutically Active Compounds And Methods Of Use Thereof
Jan, 2032

(9 years from now)

IN338474B SERVIER Therapeutically Active Compositions And Their Methods Of Use
Jan, 2033

(10 years from now)

IN201405986P1 SERVIER Therapeutically Active Compounds And Their Methods Of Use
Jan, 2033

(10 years from now)

EP2804851B1 SERVIER Lactam Derivates Useful As Inhibitors Of Mutant Idh1
Jan, 2033

(10 years from now)

EP2804851A4 SERVIER Therapeutically Active Compounds And Their Methods Of Use
Jan, 2033

(10 years from now)

EP3447052B1 SERVIER Methods Of Preparing New Idh1 Inhibitors
Jan, 2033

(10 years from now)

EP3447052A1 SERVIER Methods Of Preparing New Idh1 Inhibitors
Jan, 2033

(10 years from now)

EP2804851A1 SERVIER Lactam Derivates Useful As Inhibitors Of Mutant Idh1
Jan, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610125 SERVIER Methods and compositions for cell-proliferation-related disorders Jun, 2030

(7 years from now)

US10717764 SERVIER Therapeutically active compounds and their methods of use Jan, 2033

(10 years from now)

US10449184 SERVIER Pharmaceutical compositions of therapeutically active compounds Mar, 2035

(12 years from now)

US10799490 SERVIER Pharmaceutical compositions of therapeutically active compounds Mar, 2035

(12 years from now)

US9968595 SERVIER Pharmaceutical compositions of therapeutically active compounds Mar, 2035

(12 years from now)

US10980788 SERVIER Therapy for treating malignancies Jun, 2039

(16 years from now)

Drugs and Companies using IVOSIDENIB ingredient

Treatment: A method of treating a cancer characterized by an idh1 mutation where the cancer is relapsed or refractory acute myeloid leukemia (aml) and where the mutant idh1 has the ability to convert alpha-ketoglutarate into 2-hydroxyglutarate (2-hg); a method of treating a cancer characterized by an idh1 mutation where the cancer is newly diagnosed acute myeloid leukemia (aml) and where the mutant idh1 has the ability to convert alpha-ketoglutarate into 2-hydroxyglutarate (2-hg); A method of treating previously treated, locally advanced or metastatic cholangiocarcinoma characterized by an idh1 mutation; A method of treating acute myelogenous leukemia (aml) in a subject by administering a pharmaceutical composition where the aml is characterized by the presence of a mutant allele of idh1 and the aml is newly diagnosed; a method of treating acute myelogenous leukemia (aml) in a subject by administering a pharmaceutical composition where the aml is characterized by the presence of a mutant allele of idh1 and where the aml is relapsed/refractory; A method of treating a cancer characterized by an idh1 mutation where the cancer is newly diagnosed acute myeloid leukemia (aml); a method of treating a cancer characterized by an idh1 mutation where the cancer is relapsed or refractory acute myeloid leukemia (aml); treatment of acute myeloid leukemia (aml) with an idh1 mutation; A method of treating previously treated, locally advanced or metastatic cholangiocarcinoma characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal; treating newly diagnosed acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal; treating relapsed/refractory acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
250MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.